ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Dasgrunt, could be multiple activities.

ANI anticipates using the net proceeds from the offering to in-license, acquire or invest in additional businesses, technologies, products or assets, to fund its commercialization efforts, including, but not limited to, sales and marketing and consulting expenses related thereto, and for general corporate purposes. As part of its business, ANI actively monitors and considers various business development opportunities.

- Akorn asset bidding
- Bringing in rare disease assets
- Getting ready to rapidly ramp up a female testosterone sales force.

Given that ANIP traded above $50 on news of earnings, before institutions starting pulling it back. I figure the offering comes in above $50 offering from November 2021.